Analyst Reco. Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Delayed Nasdaq Other stock markets 11:09:33 2024-05-07 EDT			5-day change	1st Jan Change
3.815 ^USD	-0.39%		+1.19%	-10.66%

01:20pm	Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-10	Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target	03-13	MT
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5	02-20	MT
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10	12-19	MT
HC Wainwright Trims Prelude Therapeutics' Price Target to $5 From $6, Keeps Buy Rating	11-07	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $6 From $17, Keeps Buy Rating	23-10-19	MT
Barclays Adjusts Price Target on Prelude Therapeutics to $5 From $7, Maintains Equalweight Rating	23-08-04	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $17 From $15, Maintains Buy Rating	23-03-17	MT
HC Wainwright Adjusts Prelude Therapeutics' Price Target to $15 From $16, Keeps Buy Rating	22-11-17	MT
Morgan Stanley Trims Price Target on Prelude Therapeutics to $10 From $11, Maintains Equalweight Rating	22-11-15	MT
Morgan Stanley Downgrades Prelude Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $19	22-09-09	MT
Jefferies Initiates Prelude Therapeutics at Buy With $9 Price Target	22-07-29	MT
HC Wainwright Adjusts Prelude Therapeutics Price Target to $16 From $62, Maintains Buy Rating	22-05-12	MT
Morgan Stanley Adjusts Prelude Therapeutics Price Target to $19 From $20, Maintains Overweight Rating	22-03-17	MT
BofA Securities Downgrades Prelude Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $50	22-03-15	MT
Barclays Downgrades Prelude Therapeutics to Equalweight From Overweight, Adjusts Price Target to $12 From $20	22-02-28	MT
Barclays Adjusts Prelude Therapeutics' Price Target to $20 From $33, Reiterates Overweight Rating	21-11-17	MT
PRELUDE THERAPEUTICS INCORPORATED : Morgan Stanley Upgrades Prelude Therapeutics to Overweight Rating From Equal-Weight, Adjusts Price Target to $35 From $60	21-10-11	MT
PRELUDE THERAPEUTICS INCORPORATED : Barclays Adjusts Prelude Therapeutics' Price Target to $33 from $80, Keeps Overweight Rating	21-10-08	MT
PRELUDE THERAPEUTICS INCORPORATED : BofA Securities Upgrades Prelude Therapeutics to Buy From Neutral; Price Target is $60	21-07-27	MT
PRELUDE THERAPEUTICS INCORPORATED : HC Wainwright Starts Prelude Therapeutics at Buy With $62 Price Target	21-04-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Analyst Reco.

Filters